Recent Media Coverage Another milestone as Chimeric Therapeutics’ (ASX:CHM) Phase 1 CLTX CAR T trial moves ahead Read More » May 2021
Recent Media Coverage Expert Talks Ms Jennifer Chow, Chief Operating Officer of Chimeric Therapeutics Read More » May 2021
Recent Media Coverage Chimeric Achieves Milestone on Phase 1 Cell Therapy for Glioblastoma Read More » April 2021
Press Releases Successful completion of 28-day follow-up period for first patient cohort in CLTX CAR T Phase 1 trial Read More » April 2021
Press Releases Successful completion of dosing in first patient cohort for Phase 1 CLTX CAR T trial Read More » March 2021